

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

SAMARITAN PHARMACEUTICALS INC
Form 10QSB
August 14, 2002

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-QSB

(Mark One)

X QUARTERLY REPORT UNDER SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2002
Or

TRANSITIONAL REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commissions file number 000-26775

Samaritan Pharmaceuticals Inc.
(Name of small business issuer in its charter)

Nevada 88-0380402
(State or other jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or organization)

101 Convention Center Drive, Suite 310, Las Vegas, Nevada 89109
(Address of Principal Executive Offices) (Zip Code)

(702) 735-7001
Issuer's telephone number

The company had fifty-two million, seven hundred eight thousand, two hundred thirty-three shares issued and outstanding of the Common Stock issued as of June 30, 2002.

Transitional Small Business Disclosure Format (Check one): Yes___ No X

SAMARITAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

June 30, 2002

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

Consolidated Balance Sheet as of June 30, 2002 3

Consolidated Statements of Operations for the
period from Inception (September 5, 1994)

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

to June 30, 2002, and for the Six Months Ended June 30, 2002 and 2001	4
Consolidated Statements of Stockholders' Equity (Deficit) for the period from Inception (September 5, 1994) to June 30, 2002	5-6
Consolidated Statements of Cash Flows for the period from Inception (September 5, 1994) to June 30, 2002 and for the Six Months Ended June 30, 2002 and 2001	7
Notes to Consolidated Financial Statements	8-9
Item 2. Management's Discussion and Analysis of Plan of Operations	9-11
PART II - OTHER INFORMATION	
Item 1. Legal Proceedings	11-12
Item 2. Changes in Securities	12-13
Item 6. Exhibits and Reports on Form 8-K	14
Signatures	15

PART I - FINANCIAL INFORMATION

Item 1. Financial Statement

The information in this report for the three months ended June 30, 2002 and 2001 is unaudited but includes all adjustments (consisting only of normal recurring accruals, unless otherwise indicated) which Samaritan Pharmaceuticals Inc. ("Samaritan" or the "Company") considers necessary for a fair presentation of the results of operations for those periods.

The condensed consolidated financial statements should be read in conjunction with the Company's financial statements and the notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2001.

Interim results are not necessarily indicative of results for the full fiscal year.

SAMARITAN PHARMACEUTICALS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEET

(UNAUDITED)

June 30, 2002

ASSETS

CURRENT ASSETS:

Cash	\$	213,130
Subscriptions receivable		43,921
Prepaid expense		4,648

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

TOTAL CURRENT ASSETS		261,699
PROPERTY AND EQUIPMENT		24,887
OTHER ASSETS:		
Offering costs		2,284
Patent registration costs		220,785
Purchased technology rights		58,119
Deposits		15,720
TOTAL CURRENT LIABILITIES		296,908
TOTAL ASSETS	\$	583,494

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES:		
Accounts payable	\$	328,600
Accrued expenses		343,130
Common stock to be issued		121,000
Short-term borrowings		170,789
TOTAL CURRENT LIABILITIES		963,519
DEFERRED REVENUE		250,000
STOCKHOLDERS' DEFICIT:		
Common stock, 100,000,000 share authorized at \$.001 par value, 52,708,233 issued and outstanding		52,708
Additional paid-in capital		14,694,753
Deferred compensation		(247,518)
Accumulated deficit		(15,129,968)
TOTAL STOCKHOLDERS' DEFICIT		(630,025)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$	583,494

See accompanying notes to the consolidated interim financial statements.
(Unaudited)

-3-

SAMARITAN PHARMACEUTICALS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

FROM INCEPTION (SEPTEMBER 5, 1994), AND FOR THE FOR THE SIX MONTHS
AND THREE MONTHS ENDED JUNE 30, 2002 AND 2001

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

	From Inception (September 5, 1994) To June 30, 2002	For the Six Months Ended June 30,		Fo Mo
		2002	2001	
REVENUES:	\$ 50,000	\$ -	\$ -	\$
EXPENSES:				
Research and development	3,133,293	329,199	135,781	168,1
Interest	35,105	11,740	-	5,3
General and administrative	11,438,594	1,041,697	1,154,482	511,3
Depreciation and amortization	710,756	10,540	10,540	5,2
	15,317,748	1,393,176	1,300,803	690,1
INCOME (LOSS) BEFORE EXTRAORDINARY ITEM	(15,267,748)	(1,393,176)	(1,300,803)	(690,1
Extraordinary item	137,780	-	-	
NET INCOME (LOSS)	\$ (15,129,968)	\$ (1,393,176)	\$ (1,300,803)	\$ (690,1
Loss per share, basic & diluted:				
Before extraordinary item	\$ (1.12)	\$ (0.03)	\$ (0.06)	\$ (0
Extraordinary item, per share	0.01	-	-	
Basic and diluted	\$ (1.11)	\$ (0.03)	\$ (0.06)	\$ (0
Weighted average number of shares outstanding:				
Basic and diluted	13,611,598	42,748,802	22,516,379	44,970,

See accompanying notes to the consolidated interim financial statements.

(Unaudited)

-4-

SAMARITAN PHARMACEUTICALS, INC.
(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIT
FROM INCEPTION (SEPTEMBER 5, 1994) TO JUNE 30, 2002

Number Par Value Reserved Additional

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

	of Shares	Common Stock	for Conversion	Paid in Capital	Warrants	C
	-----	-----	-----	-----	-----	-----
Inception at September 5, 1994	-	-	-	-	-	-
Shares issued for cash, net of offering costs	6,085,386	609	-	635,481	-	-
Warrants issued for cash	-	-	-	-	5,000	-
Shares issued as compensation for services	714,500	71	-	1,428,929	-	-
Net loss	-	-	-	-	-	-
December 31, 1996	6,799,886	680	-	2,064,410	5,000	-
Issuance of stock, prior to acquisition	206,350	21	-	371,134	-	-
Acquisition of subsidiary for stock	1,503,000	150	-	46,545	-	-
Shares of parent redeemed, par value \$.001	(8,509,236)	(851)	-	851	-	-
Shares of public subsidiary issued, par value \$.001	7,689,690	7,690	820	(8,510)	-	-
Net loss	-	-	-	-	-	-
December 31, 1997	7,689,690	7,690	820	2,474,430	5,000	-
Conversion of parent's shares	696,022	696	(696)	-	-	-
Shares issued for cash, net of offering costs	693,500	694	-	605,185	-	-
Shares issued in cancellation of debt	525,000	525	-	524,475	-	-
Shares issued as compensation	400,000	400	-	349,600	-	-
Net loss	-	-	-	-	-	-
December 31, 1998	10,004,212	10,005	124	3,953,690	5,000	-
Conversion of parent's shares	13,000	13	(13)	-	-	-
Shares issued in cancellation of debt	30,000	30	-	29,970	-	-
Shares issued for cash, net of offering costs	45,000	45	-	41,367	-	-
Shares issued as compensation	3,569,250	3,569	-	462,113	-	-
Detachable warrants issued	-	-	-	-	152,125	-
Detachable warrants exercised	100,000	100	-	148,900	(149,000)	-
Debentures converted to stock	1,682,447	1,682	-	640,438	-	-
Net loss	-	-	-	-	-	-
December 31, 1999	15,443,909	15,444	111	5,276,478	8,125	-

See accompanying notes to the consolidated, interim financial statements.
(Unaudited)

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

Conversion of parent's shares	128,954	129	(111)	(18)	-
Shares issued for cash, net of offering costs	1,575,192	1,575	-	858,460	-
Shares issued in cancellation of debt	875,000	875	-	660,919	-
Shares issued in cancellation of accounts payable	100,000	100	-	31,165	-
Shares issued as compensation	3,372,945	3,373	-	2,555,094	-
Warrants exercised	38,807	39	-	3,086	(3,125)
Warrants expired	-	-	-	5,000	(5,000)
Net loss	-	-	-	-	-
<hr/>					
December 31, 2000	21,534,807	21,535	-	9,390,184	-
Shares issued for cash, net of offering costs	6,497,088	6,497	-	1,257,758	-
Shares issued as compensation	9,162,197	9,162	-	1,558,599	-
Shares issued on previously purchased shares	342,607	342	-	188,208	-
Shares issued in cancellation of accounts payable	200,000	200	-	68,880	-
Amortization of deferred compensation	-	-	-	-	-
Stock options issued for services	-	-	-	439,544	-
Net loss	-	-	-	-	-
<hr/>					
December 31, 2001	37,736,699	\$ 37,736	\$	\$12,903,173	\$
Shares issued for cash, net of offering costs	7,705,000	7,705	-	754,300	-
Shares issued as compensation	1,070,483	1,070	-	159,582	-
Shares issued on previously purchased shares	50,000	50	-	4,950	-
Shares issued in cancellation of accounts payable	3,866,051	3,867	-	539,709	-
Amortization of deferred compensation	-	-	-	-	-
Shares issued in cancellation of debt	2,280,000	2,280	-	332,739	-
Net loss	-	-	-	-	-
<hr/>					
June 30, 2002	52,708,233	\$ 52,708	\$	\$14,694,753	\$
<hr/>					

See accompanying notes to the consolidated, interim financial statements.
(Unaudited)

-6-

SAMARITAN PHARMACEUTICALS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

See accompanying notes to the consolidated interim financial statements.
(Unaudited)

-7-

Samaritan Pharmaceuticals, Inc.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements (Unaudited)
June 30, 2002

1. Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

The interim unaudited consolidated financial statements contained herein includes, in management's opinion, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of the company's financial position, results of operations, and cash flows for the periods presented.

The results of operations for the interim period shown on this report are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the Company's consolidated financial statements and notes for the year ended December 31, 2001 included in the Company's Annual Report on Form 10-K.

2. Net Loss Per Share

Basic and diluted net loss per share available to common stockholders has been calculated by dividing net loss by the weighted average number of common shares outstanding during the period. All potential common shares have been excluded from the calculation of weighted average common shares outstanding since their inclusion would be anti-dilutive.

Stock options and warrants to purchase shares of common stock were outstanding at June 30, 2002, but were not included in the computation of diluted net loss per common share because they were anti-dilutive. The exercise of options and warrants outstanding as of June 30, 2002, could generate proceeds to the Company and could potentially dilute earnings per share in the future.

-8-

3. Stockholders' Equity

During the three months ended June 30, 2002, management notes the following shares were issued.

No. of shares	Issued Pursuant To	Price/valuation
810,000	Sale of Registered Common Stock	\$ 121,870
3,479,629	In settlement of accounts payable	\$ 477,100
4,545,000	Restricted Stock Private Placements	\$ 454,500
-----		-----
8,834,629		\$ 1,053,470

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

4. Legal Proceedings

Management notes that the Company was involved in litigation as of June 30, 2002. Please see Part II- Other Information, Item 1, Legal Proceedings.

5. Forward-Looking Statements

This quarter report contains forward-looking statements. These statements relate to future events or Samaritan Pharmaceutical's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "intend," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risks outline in "Risk Factors" in our Form 10-KSB filed April 26, 2002.

Although Samaritan Pharmaceuticals, Inc. believes the expectations reflected in the forward-looking statements are reasonable, Samaritan Pharmaceuticals, Inc. cannot guarantee future results, events, levels of activity, performance, or achievements. Moreover, neither Samaritan Pharmaceuticals, Inc. nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. Samaritan Pharmaceuticals, Inc. does not assume any obligation to update any of the forward-looking statements after the date of this report, to conform such statements to actual results, or to changes in Samaritan's expectations.

Item 2. Management's Discussion and Analysis or Plan of Operation

The section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Samaritan Pharmaceutical's 2001 Form 10KSB filed April 26, 2002 is hereby incorporated herein by reference.

Anticort(TM) for HIV

The most advanced of Samaritan's pipeline is Anticort(TM) has promising, early, "first blush data", from its HIV Phase II Anticort(TM) clinical trial. Therefore, a detailed analysis of data is being conducted to submit to peer review journals, present at a medical conference, file for additional patent protections with other indications, and prepare for our FDA submissions. We expect the FDA to request at least a couple of Phase III human trials to confirm safety and the lack of side effects. Since the data appears promising, we hope to achieve a licensing deal with a Pharma partner. We have a signed CDA with a major pharmaceutical, for Anticort(TM).

-9-

New Transgenic Alzheimer's Rat Model

We are finalizing the engineering of our "transgenic rat model" which could be used by major Pharma to test their Alzheimer's drugs. A transgenic rat is being engineered to develop Alzheimer's; very similar to the way Alzheimer's is developed in humans. This would enable scientists to advance their understanding of the disease and test drug candidates for safety and efficacy, thereby, saving research time and money.

Breast Cancer Diagnostic

A clear advantage of our breast cancer diagnostic is in its ability to expeditiously predict the aggressiveness of a breast cancer tumor and its

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

ability to spread when time is critical. Today, the current breast cancer diagnostic used by surgeons takes possibly two weeks longer than our diagnostic to attain a similar diagnosis, and research indicates our diagnostic has a much higher accuracy rate.

Alzheimer's Diagnostic

A simple blood test is the clear advantage of our Alzheimer's diagnostic rather than a brain scan. Early diagnosis, before the onset of symptoms and debilitation could, with treatment, lengthen the progression of Alzheimer's.

Samaritan Pharmaceuticals Inc. announced that it has identified a small molecule drug that induces human neuron differentiation from precursor cells -- that is, they transform cells from embryonic early-stage development, to an adult state. Stem cells, cells that give rise to a lineage of cells, are immature precursors that can become neurons; they exist in both embryonic and adult brain cells.

Using a model of human embryonal carcinoma stem cells, the Georgetown/Samaritan Research team screened a number of small molecules for their ability to induce neuronal differentiation. One of the molecules discovered reduced levels in Alzheimer's brain biopsies compared to age-matched controls, was found to induce neuronal differentiation as seen by the formation of networks of axon bundles and the expression of markers specific to adult human differentiated neurons. This molecule was found to be devoid of tumorigenic activity -- that is, capable of causing tumors, in contrast to other previously reported inducers of neuronal differentiation.

The Georgetown team, funded by a collaborative agreement by Samaritan Pharmaceuticals, is now proceeding to test this molecule in animal models. Although this molecule is early in its development, if this Alzheimer's discovery becomes a successful drug, it could give incredible, long-sought-after hope for patients who suffer with Alzheimer's and related diseases. The diseases or conditions that could be positively impacted by this discovery include: neurogenetic defects, spinal cord injury, spinal motor atrophy, stroke, multi-infarct dementia, amyotrophic lateral sclerosis and diseases where "neuronal regeneration" may be the treatment of choice for neurodegenerative disorders, such as Alzheimer's.

Samaritan Pharmaceuticals Inc. and Georgetown University, announced that Dr. Vassili Papadopoulos, Samaritan's Chief Scientific Officer, recently presented finding that "elevated levels of cholesterol play an even greater role in the development of Alzheimer's," to the Endocrine Society. An elevated Cholesterol/Alzheimer's Link found by researchers at Georgetown University Medical Center uncovered a strong link between elevated blood cholesterol levels and the development of Alzheimer's disease. APP, a protein found in several major organs including the brain and heart, is present in all people. Its normal function in the body is unknown, but in people with Alzheimer's, it is processed abnormally and converted to another protein called beta-amyloid. When fragments of this protein break off, they become entangled, leading to the plaques that are one of the characteristic structural abnormalities found in the brains of people suffering from Alzheimer's. "High cholesterol levels also increase the rate at which the amyloid beta form(s) the tangles that kill brain cells," researchers said. They also found that high cholesterol increases the production of another protein, called APOE, which mainly is responsible for flushing cholesterol out of the cell. Too much APOE results in the accumulation of free cholesterol, which is toxic to human nerve cells. This Cholesterol discovery is related to a patent licensed by Samaritan Pharmaceuticals from Georgetown University.

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

The Company has incurred research and development stage losses since its inception. These losses consist primarily of research and related expenditures, marketing costs, consulting, administrative overhead and expenses, incurred while the Company seeks to complete development of its products, which includes clinical human trials to obtain FDA approval for Anticort(TM). No significant revenues have been earned by the Company, or cash flow from operations, to help pay these operating needs.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

The response to this item is incorporated by reference from the discussion responsive thereto under the caption "Legal Proceedings" in our Form 10-KSB filed April 26, 2002.

On June 19, 2002, a District Court Judge decreed, that a Derivative Action Plaintiff was defrauded by Alfred Sapse, the initiator of lawsuit No. A420721 in the District Court Clark County, Nevada, Sapse included the plaintiff's name, unbeknownst to the plaintiff, in a lawsuit against Samaritan Pharmaceuticals. Samaritan, as a defendant was victorious and awarded monies. This June 19, 2002 court order goes on to say that a verification signed by the plaintiff was fraudulently presented to him as simply a confirmation of stock ownership, and the plaintiff had no knowledge that Alfred Sapse had filed a lawsuit on the plaintiffs' behalf against Samaritan Pharmaceuticals. Based upon the foregoing, the court ordered, adjudged, and decreed that the plaintiff was defrauded by Alfred Sapse by his involuntary inclusion of this plaintiff in the derivative action lawsuit, and that Samaritan could release the plaintiff from any obligations of the November 18, 2001, Order and Judgment against Sapse and all the Plaintiffs in the lawsuit. The November 18, 2001 order stated that the derivative action plaintiffs pay Samaritan Pharmaceuticals a \$100,000 cash bond which was posted by Alfred Sapse plus other monies.

On June 20, 2002, based on the evidence recently provided for in a lawsuit filed by Samaritan on October 3, 2000 against Alfred T. Sapse and Cortisol Medical Research, a letter was sent from the attorney for Steroidogenesis Inhibitors, Inc. (S.I.), a subsidiary of Samaritan Pharmaceuticals, Inc., to Steroidogenesis Inhibitors Canada, Inc. (S.I. Canada). The letter was sent to the address stated in the contract between S.I. and S.I. Canada. The purpose of the letter was to inform S.I. Canada that the Anticort(TM) license granted to S.I. Canada was not a valid conveyance. According to a judgment entered by a United States court of competent jurisdiction, the Company believes Alfred Sapse and Cortisol Medical Research didn't own the technology it purported to license to S.I. and S.I. Canada since Alfred Sapse had previously assigned all Anticort rights including improvements to Spectrum Pharmaceuticals in May 1990. Therefore, the grant of any license under the Agreement dated July 7, 1997 between S.I. Canada and S.I. is ineffective and void. S.I.'s attorney also strongly suggested that S.I. Canada discontinue conducting any business to the extent it involves Anticort.

-11-

The attorneys for S.I. have based this belief in part to the following:

On May 22, 1990, Alfred Sapse the inventor of Anticort(TM) (U.S Patent Numbers 5,064,858 and 4,956,391) assigned all patent rights with improvements on the discovery, via an agreement to Spectrum Pharmaceuticals. (See Exhibit 10.3)

On May 14, 1999, Spectrum Pharmaceuticals Corporation assigned Anitcort(TM) (U.S. Patent Numbers 5,064,858 and 4,956,391) to Linda Johnson with improvements on stated patents. (See Exhibit 10.2)

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

On September 10, 2000 the Company purchased Anticort(TM) (U.S. Patent Numbers 5,064,858 and 4,956,391). (See Exhibit 10.1) The patent rights transferred to Samaritan Pharmaceuticals include the assignment rights as set forth in the "Assignment of Inventions" (Exhibit 10.2) issued to Linda Johnson which included improvements on Anticort(TM).

On October 3, 2000, the company filed a lawsuit against Alfred Sapse, Cortisol Medical Research, Inc. and Renee Sapse seeking to recover 5,100,000 shares which were issued based upon Alfred Sapse's false representations of ownership of the Anticort(TM) technology. In addition and based on recent evidence, the Company now strongly believes Sapse and Cortisol Medical Research knowingly granted an exclusive worldwide license to Anticort(TM) technology and all know-how related to the use of Anticort(TM), knowing the rights were assigned previously in May 1990 to Spectrum Pharmaceuticals. (See Exhibit 10.3)

The section entitled "Legal Proceeding" in Samaritan Pharmaceutical's 2001 Form 10KSB filed April 26, 2002 is hereby incorporated herein by reference.

Item 2. Changes in Securities.

Securities, unregistered, were sold by the Company in the second quarter of the fiscal year covered by the Report under an exemption from registration. The title of these securities was the Common Stock of the Company. They were sold for cash, unless otherwise noted in this section, and were sold in private transactions to persons believed to be of a class of private investors, acting on their own, comprised of "accredited investors" (as such term is defined in Regulation D of the U.S. Securities and Exchange Commission or "SEC") and a limited number of non-accredited investors. All investors, to the best knowledge of the Company, are not affiliated with the Company, and purchased the shares with apparent investment intent. The Company relied upon, among other possible exemptions, Section 4(2) of the Securities Act of 1933, as amended. It's reliance on said exemption was based upon the fact that no public solicitation was used by the Company in the offer or sale, and that the securities were legend shares, along with a notation at the respective transfer agent, restricting the shares from sale or transfer as is customary with reference to Rule 144 of the SEC. The following information identifies the date, and amount of shares sold during the first quarter:

-12-

Date	Name of Class	Amount of Shares	Total Offering
April-June 2002	Restricted Stock Private Placements	4,545,000	\$ 454,500
April-June 2002	Settlement of Accounts Payable	3,479,629	\$ 477,100

The SEC declared effective the Company's registration statement on Form SB-2, Commission Registration No. 333-52296, on December 20, 2000 (as amended and supplemented from time to time, "Registration Statement"). Under the Registration Statement, certain selling shareholders may sell shares of Common Stock, which is the title of the class of securities registered, acquired from the Company. The Company does not receive any proceeds from the sale of securities being offered by the selling shareholders under the Registration Statement. The Company registered the shares for sale to provide the selling shareholders with freely tradable securities, but the registration of the shares does not necessarily mean that any of the shares will be offered or sold by the selling shareholders. However, we may receive payments under agreements relating to the shares and may receive proceeds from the exercise of warrants. Such proceeds are intended for use as to working capital and other corporate

Edgar Filing: SAMARITAN PHARMACEUTICALS INC - Form 10QSB

purposes. The offering under the Registration Statement has not terminated. The Registration Statement registered a total of 11,825,000 shares for a total anticipated offering price, subject to conditions, of \$20,000,000. The amount of shares sold by the selling shareholder during this quarter is believed to be 810,000 for aggregate proceeds of \$121,870. The Company received, under its agreements as noted above, proceeds of \$121,870 and incurred, in connection with the registration, estimated expenses of \$3,000 for legal, printing, and related offering expenses, with net proceeds to the Company of approximately \$118,870 used primarily for working capital, legal fees and for payments to Georgetown University.

-13-

Item 6. Exhibits and Reports on Form 8-K.

(a) REPORTS ON FORM 8-K

Samaritan Pharmaceuticals did not file any on Form 8-K during the quarter for which this report is filed.

(b) EXHIBITS

Listed below are all exhibits filed as part of this report. Some exhibits are filed by the Registrant with the Securities and Exchange Commission pursuant to Rule 12b-32 under the Securities Exchange Act of 1934, as amended.

Exhibits

No.	Description
2.1	Agreement and Plan of Reorganization (1)
3.1	Articles of Incorporation, as amended and restated *
3.2	By-Laws, as amended and restated (3)
4.1	Form of common stock certificate (1)
4.2	1997 Stock Option Plan (1)
4.3	2001 Stock Option Plan (4)
10.1	Assignment between Linda Johnson and the Company dated September 6, 2000. *
10.2	Assignment between Linda Johnson and Spectrum Pharmaceuticals Corporation dated May 14, 1999. *
10.3	Agreement containing the assignment of U.S. Patent Application 07/233,247 with improvements dated May 22, 1990. *
10.4	Agreement between AIDS Research Alliance Agreement and the Company dated March 5, 1999 (1)
10.5	Common Stock Purchase Agreement between Company and Fusion Capital Fund II, LLC, dated November 2, 2000 (2)
10.6	Form of Registration Rights Agreement between Company and Fusion Capital Fund II, LLC. (2)
10.7	Agreement between Samaritan Pharmaceuticals, Inc. and Doug Bessert + *
10.8	Agreement between Samaritan Pharmaceuticals, Inc. and Eugene Boyle + *
10.9	Agreement between Samaritan Pharmaceuticals, Inc and Janet Greeson + *
10.10	Samaritan Pharmaceuticals, Inc.'s Rabbi Trust + *
21.0	List of Subsidiaries (1)

* Filed herewith.

+ Management contract or compensatory plan or arrangement.

(1) Filed as an exhibit to Form 10-SB, including any amendments, on July 21, 1999 and incorporated herein by reference.

(2) Filed as an exhibit Form SB-2, including any amendments, on

(3) Filed as an exhibit to Form 10KSB, including any amendments, on April 3, 2001 and incorporated herein by reference.

(4) Filed as an exhibit to DEF 14 A, including any amendments, on April 3, 2001 and incorporated herein by reference

-14-

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SAMARITAN PHARMACEUTICALS, INC

Dated: August 14, 2002

By: /s/ Janet Greeson, Ph.D.

Janet Greeson, Ph.D.
President, C.E.O., Chairman

Dated: August 14, 2002

By: /s/ Eugene Boyle

Eugene Boyle
CFO, COO, Director

Dated: August 14, 2002

By: /s/ Doug Bessert

Doug Bessert
Executive Vice President, Director

-15-

